Srinivas Maddi
Srinivas Maddi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Jeevan Karthik Madavareddi
Acubiosys Private Limited, Hyderabad, India
3 shared publications - Lokesh Jiraka
Acubiosys Private Limited, Hyderabad, India
2 shared publications - Manaswini Cheruku
Acubiosys Private Limited, Hyderabad, India
2 shared publications - Aruna Eerla
University College of Pharmaceutical Sciences, Palamuru University, Mahabub Nagar, India
1 shared publication - Bajee Shaik
ACUBIOSYS Private Limited, Telangana State Industrial Infrastructure Corporation Limited—Industrial Area Local Authority (TSIIC‐IALA) Hyderabad India
1 shared publication Biswajit Swain
1 shared publication
Latest Publications
- Open Access
- 9 August 2026
- Published by Science Publishing Group in Journal of Drug Design and Medicinal Chemistry
- Vol. 12 (2) , 29-45
Machine Learning-Assisted in Silico Identification of Phytoconstituents as Potential NS5 RdRp Inhibitors for Dengue Therapeutics
The escalating global burden of dengue virus (DENV) infection and the lack of specific antiviral therapies necessitate the development of effective therapeutics targeting the highly conserved non-structural protein 5 RNA-dependent RNA polymerase (NS5 RdRp). This study employed an integrated computer-aided drug discovery (CADD) and machine learning (ML) framework to screen a library of 14 phytoconstituents against DENV-2 NS5 RdRp. Following molecular docking, the top-ranked compounds were evaluated for pharmacokinetic safety through cross-docking with CYP3A4, OATP1B1, and OATP1B3, complemented by ADMET prediction using SwissADME and ProTox-II. In parallel, ML-based quantitative structure-activity relationship (QSAR) models using Random Forest (RF) and Extreme Gradient Boosting (XGBoost) were developed using hybrid descriptors comprising Morgan fingerprints, physicochemical properties, experimental IC50 values, and docking scores derived from validated DENV RdRp inhibitors. Docking analysis identified Glycyrrhizin, Curcumin, Boswellic acid, Mangiferin, Azadirachtin, and Forskolin as promising inhibitors, exhibiting binding affinities comparable to or greater than those of remdesivir. Although several lead compounds demonstrated potential interactions with CYP3A4, their weak binding to OATP1B1 and OATP1B3 suggested a reduced risk of transporter-mediated toxicity and favorable hepatic safety, supported by ADMET predictions indicating favorable drug-like properties. Among the developed ML- based QSAR models, XGBoost outperformed RF in predicting nonlinear structure-activity relationships. Overall, the integrated molecular docking, pharmacokinetic profiling, and ML-based QSAR analyses identified Glycyrrhizin, Curcumin, Boswellic acid, and Azadirachtin as the most promising antiviral lead scaffolds and demonstrate the value of AI-driven drug discovery for accelerating antiviral lead identification. Further in vitro and in vivo studies are warranted to validate their therapeutic efficacy and safety.
- 9 August 2026
- Published by Science Publishing Group in Journal of Drug Design and Medicinal Chemistry
- Vol. 12 (2) , 29-45
Open AccessMachine Learning-Assisted in Silico Identification of Phytoconstituents as Potential NS5 RdRp Inhibitors for Dengue Therapeutics
The escalating global burden of dengue virus (DENV) infection and the lack of specific antiviral therapies necessitate the development of effective therapeutics targeting the highly conserved non-structural protein 5 RNA-dependent RNA polymerase (NS5 RdRp). This study employed an integrated computer-aided drug discovery (CADD) and machine learning (ML) framework to screen a library of 14 phytoconstituents against DENV-2 NS5 RdRp. Following molecular docking, the top-ranked compounds were evaluated for pharmacokinetic safety through cross-docking with CYP3A4, OATP1B1, and OATP1B3, complemented by ADMET prediction using SwissADME and ProTox-II. In parallel, ML-based quantitative structure-activity relationship (QSAR) models using Random Forest (RF) and Extreme Gradient Boosting (XGBoost) were developed using hybrid descriptors comprising Morgan fingerprints, physicochemical properties, experimental IC50 values, and docking scores derived from validated DENV RdRp inhibitors. Docking analysis identified Glycyrrhizin, Curcumin, Boswellic acid, Mangiferin, Azadirachtin, and Forskolin as promising inhibitors, exhibiting binding affinities comparable to or greater than those of remdesivir. Although several lead compounds demonstrated potential interactions with CYP3A4, their weak binding to OATP1B1 and OATP1B3 suggested a reduced risk of transporter-mediated toxicity and favorable hepatic safety, supported by ADMET predictions indicating favorable drug-like properties. Among the developed ML- based QSAR models, XGBoost outperformed RF in predicting nonlinear structure-activity relationships. Overall, the integrated molecular docking, pharmacokinetic profiling, and ML-based QSAR analyses identified Glycyrrhizin, Curcumin, Boswellic acid, and Azadirachtin as the most promising antiviral lead scaffolds and demonstrate the value of AI-driven drug discovery for accelerating antiviral lead identification. Further in vitro and in vivo studies are warranted to validate their therapeutic efficacy and safety.
- Open Access
- 14 April 2026
- Published by Peertechz Publications Private Limited in International Journal of Pharmaceutical Sciences and Developmental Research
- Vol. 12 (1) , 006-016
Repaglinide-Indinavir Pharmacokinetic and Pharmacodynamic Interaction: Non-Clinical Evaluation in Hepatic and Diabetic Impairment models
Background: Repaglinide, used for postprandial glucose control, is extensively metabolized by cytochrome P450 enzymes and transported by OATP and P-glycoprotein, making it susceptible to pharmacokinetic interactions. Indinavir, an antiviral protease inhibitor, affects metabolic and transport pathways, thereby altering the pharmacokinetic and pharmacodynamic profile of repaglinide. This study investigated the interaction between repaglinide and indinavir in healthy rats and in rat models of diabetes and hepatic impairment. Methods: Clinical doses of indinavir and repaglinide were converted to rat-equivalent doses using the Body Surface Area (BSA) method. Healthy, diabetic, and hepatic-impaired rats were administered indinavir (78 mg/kg, P.O), followed by repaglinide (0.5 mg/kg, P.O). Plasma concentrations of repaglinide were determined, and pharmacokinetic parameters, including maximum plasma concentration (Cmax), Area Under the Concentration–time curve (AUC), elimination half-life (t½), and plasma clearance (CL), were evaluated. Blood glucose levels were also measured to assess pharmacodynamic effects. Results: In the presence of indinavir, repaglinide exhibited significantly altered pharmacokinetics in normal (P < 0.005), diabetic (P < 0.0001), and hepatic-impaired (P < 0.0001) rats, characterized by increased maximum plasma concentration (Cmax), Area Under the Concentration–time curve (AUC), and elimination half-life (t½), along with a significant reduction in plasma clearance (CL) across all groups compared with repaglinide alone. Pharmacodynamically, repaglinide in combination with indinavir produced a markedly greater (P < 0.0001) hypoglycemic effect in diabetic and hepatic-impaired rats than repaglinide administered alone. Conclusion: The study demonstrates a significant pharmacokinetic and pharmacodynamic interaction between indinavir and repaglinide, characterized by enhanced bioavailability and reduced total body clearance of repaglinide. These effects are likely mediated by the inhibitory action of indinavir on cytochrome P450 enzymes, as well as on OATP and P-glycoprotein transporters.
- 14 April 2026
- Published by Peertechz Publications Private Limited in International Journal of Pharmaceutical Sciences and Developmental Research
- Vol. 12 (1) , 006-016
Open AccessRepaglinide-Indinavir Pharmacokinetic and Pharmacodynamic Interaction: Non-Clinical Evaluation in Hepatic and Diabetic Impairment models
Background: Repaglinide, used for postprandial glucose control, is extensively metabolized by cytochrome P450 enzymes and transported by OATP and P-glycoprotein, making it susceptible to pharmacokinetic interactions. Indinavir, an antiviral protease inhibitor, affects metabolic and transport pathways, thereby altering the pharmacokinetic and pharmacodynamic profile of repaglinide. This study investigated the interaction between repaglinide and indinavir in healthy rats and in rat models of diabetes and hepatic impairment. Methods: Clinical doses of indinavir and repaglinide were converted to rat-equivalent doses using the Body Surface Area (BSA) method. Healthy, diabetic, and hepatic-impaired rats were administered indinavir (78 mg/kg, P.O), followed by repaglinide (0.5 mg/kg, P.O). Plasma concentrations of repaglinide were determined, and pharmacokinetic parameters, including maximum plasma concentration (Cmax), Area Under the Concentration–time curve (AUC), elimination half-life (t½), and plasma clearance (CL), were evaluated. Blood glucose levels were also measured to assess pharmacodynamic effects. Results: In the presence of indinavir, repaglinide exhibited significantly altered pharmacokinetics in normal (P < 0.005), diabetic (P < 0.0001), and hepatic-impaired (P < 0.0001) rats, characterized by increased maximum plasma concentration (Cmax), Area Under the Concentration–time curve (AUC), and elimination half-life (t½), along with a significant reduction in plasma clearance (CL) across all groups compared with repaglinide alone. Pharmacodynamically, repaglinide in combination with indinavir produced a markedly greater (P < 0.0001) hypoglycemic effect in diabetic and hepatic-impaired rats than repaglinide administered alone. Conclusion: The study demonstrates a significant pharmacokinetic and pharmacodynamic interaction between indinavir and repaglinide, characterized by enhanced bioavailability and reduced total body clearance of repaglinide. These effects are likely mediated by the inhibitory action of indinavir on cytochrome P450 enzymes, as well as on OATP and P-glycoprotein transporters.
- Top Cited PapersOpen Access
- 7 June 2025
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 13 (3) , 2772
Leveraging machine learning models in evaluating ADMET properties for drug discovery and development
Background and purpose: The evaluation of ADMET properties remains a critical bottleneck in drug discovery and development, contributing significantly to the high attrition rate of drug candidates. Traditional experimental approaches are often time-consuming, cost-intensive, and limited in scalability. This review aims to investigate how recent advances in machine learning (ML) models are revolutionizing ADMET prediction by enhancing accuracy, reducing experimental burden, and accelerating decision-making during early-stage drug development. Experimental approach: This article systematically examines the current landscape of ML applications in ADMET prediction, including the types of algorithms employed, common molecular descriptors and datasets used, and model development workflows. It also explores public databases, model evaluation metrics, and regulatory considerations relevant to computational toxicology. Emphasis is placed on supervised and deep learning techniques, model validation strategies, and the challenges of data imbalance and model interpretability. Key results: ML-based models have demonstrated significant promise in predicting key ADMET endpoints, outperforming some traditional quantitative structure - activity relationship (QSAR) models. These approaches provide rapid, cost-effective, and reproducible alternatives that integrate seamlessly with existing drug discovery pipelines. Case studies discussed in this review illustrate the successful deployment of ML models for solubility, permeability, metabolism, and toxicity predictions. Conclusion: Machine learning has emerged as a transformative tool in ADMET prediction, offering new opportunities for early risk assessment and compound prioritization. While challenges such as data quality, algorithm transparency, and regulatory acceptance persist, continued integration of ML with experimental pharmacology holds the potential to substantially improve drug development efficiency and reduce late-stage failures.
- 7 June 2025
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 13 (3) , 2772
Top Cited PapersOpen AccessLeveraging machine learning models in evaluating ADMET properties for drug discovery and development
Background and purpose: The evaluation of ADMET properties remains a critical bottleneck in drug discovery and development, contributing significantly to the high attrition rate of drug candidates. Traditional experimental approaches are often time-consuming, cost-intensive, and limited in scalability. This review aims to investigate how recent advances in machine learning (ML) models are revolutionizing ADMET prediction by enhancing accuracy, reducing experimental burden, and accelerating decision-making during early-stage drug development. Experimental approach: This article systematically examines the current landscape of ML applications in ADMET prediction, including the types of algorithms employed, common molecular descriptors and datasets used, and model development workflows. It also explores public databases, model evaluation metrics, and regulatory considerations relevant to computational toxicology. Emphasis is placed on supervised and deep learning techniques, model validation strategies, and the challenges of data imbalance and model interpretability. Key results: ML-based models have demonstrated significant promise in predicting key ADMET endpoints, outperforming some traditional quantitative structure - activity relationship (QSAR) models. These approaches provide rapid, cost-effective, and reproducible alternatives that integrate seamlessly with existing drug discovery pipelines. Case studies discussed in this review illustrate the successful deployment of ML models for solubility, permeability, metabolism, and toxicity predictions. Conclusion: Machine learning has emerged as a transformative tool in ADMET prediction, offering new opportunities for early risk assessment and compound prioritization. While challenges such as data quality, algorithm transparency, and regulatory acceptance persist, continued integration of ML with experimental pharmacology holds the potential to substantially improve drug development efficiency and reduce late-stage failures.
- Open Access
- 20 September 2024
- Published by Cell Nature and Science Publisher in Nature Cell and Science
- Vol. 000 (000) , 000
Patient-derived Tumor Organoids: Generation and Applications in Disease Modeling and Personalized Therapy
Tumor heterogeneity is a significant challenge in cancer treatment, as it often leads to therapeutic resistance and tumor recurrence. Commonly used tumor models, such as patient-derived xenografts and patient-derived tumor cells, have several limitations. Recent advances in three-dimensional (3D) organoid culture technology have introduced an alternative model that mimics the physiological environment of tissue in a dish. The use of organoid technology in oncology offers various advantages in accelerating cancer research. Patient-derived tumor organoids (PDTOs) fill gaps left by patient-derived tumor cell and patient-derived xenograft models due to their pathophysiological similarities to natural metastasis and carcinogenesis. For this reason, PDTOs can be used as an approach for drug assessment, the discovery of prognostic biomarkers, and the identification of resistance mechanisms to help tailor personalized therapies for combating cancer resistance and recurrence. Additionally, the technology can be utilized for biobanking and discovering novel anti-cancer molecules, as well as validating drugs approved by the U.S. Food and Drug Administration with the potential for repurposing in cancer therapy. This offers new treatment options and can extend the life expectancy of cancer patients. In this review, we highlight the most recent developments in oncology-related tumoroid research, with particular emphasis on PDTOs and their potential for translational research, especially in the testing of anti-cancer drugs.
- 20 September 2024
- Published by Cell Nature and Science Publisher in Nature Cell and Science
- Vol. 000 (000) , 000
Open AccessPatient-derived Tumor Organoids: Generation and Applications in Disease Modeling and Personalized Therapy
Tumor heterogeneity is a significant challenge in cancer treatment, as it often leads to therapeutic resistance and tumor recurrence. Commonly used tumor models, such as patient-derived xenografts and patient-derived tumor cells, have several limitations. Recent advances in three-dimensional (3D) organoid culture technology have introduced an alternative model that mimics the physiological environment of tissue in a dish. The use of organoid technology in oncology offers various advantages in accelerating cancer research. Patient-derived tumor organoids (PDTOs) fill gaps left by patient-derived tumor cell and patient-derived xenograft models due to their pathophysiological similarities to natural metastasis and carcinogenesis. For this reason, PDTOs can be used as an approach for drug assessment, the discovery of prognostic biomarkers, and the identification of resistance mechanisms to help tailor personalized therapies for combating cancer resistance and recurrence. Additionally, the technology can be utilized for biobanking and discovering novel anti-cancer molecules, as well as validating drugs approved by the U.S. Food and Drug Administration with the potential for repurposing in cancer therapy. This offers new treatment options and can extend the life expectancy of cancer patients. In this review, we highlight the most recent developments in oncology-related tumoroid research, with particular emphasis on PDTOs and their potential for translational research, especially in the testing of anti-cancer drugs.
- 12 April 2023
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 33 (3) , 610-616
A Validated HPLC Method for the Simultaneous Quantification of Curcumin, Silybin, and Psoralen: Application to Phytopharmaceuticals
- 12 April 2023
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 33 (3) , 610-616
A Validated HPLC Method for the Simultaneous Quantification of Curcumin, Silybin, and Psoralen: Application to Phytopharmaceuticals
- Open Access
- 11 October 2022
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 11 (1) , 1-32
Role of in vitro two-dimensional (2D) and three-dimensional (3D) cell culture systems for ADME-Tox screening in drug discovery and development: a comprehensive review
Drug discovery and development have become a very time-consuming and expensive process. Preclinical animal models have become the gold standard for studying drug pharmacokinetic and toxicity parameters. However, the involvement of a huge number of animal subjects and inter-species pathophysiological variations between animals and humans has provoked a lot of debate, particularly because of ethical concerns. Although many efforts are being established by biotech and pharmaceutical companies for screening new chemical entities in vitro before preclinical trials, failures during clinical trials are still involved. Currently, a large number of two- dimensional (2D) in vitro assays have been developed and are being developed by researchers for the screening of compounds. Although these assays are helpful in screening a huge library of compounds and have shown perception, there is a significant lack in predicting human Absorption, Distribution, Metabolism, Excretion and Toxicology (ADME-Tox). As a result, these assays cannot completely replace animal models. The recent inventions in three-dimensional (3D) cell culture-based assays like organoids and micro-physiological systems have shown great potential alternative tools for predicting the compound pharmacokinetic and pharmacodynamic fate in humans. In this comprehensive review, we have summarized some of the most commonly used 2D in vitro assays and emphasized the achievements in next-generation 3D cell culture-based systems for predicting the compound ADME-Tox.
- 11 October 2022
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 11 (1) , 1-32
Open AccessRole of in vitro two-dimensional (2D) and three-dimensional (3D) cell culture systems for ADME-Tox screening in drug discovery and development: a comprehensive review
Drug discovery and development have become a very time-consuming and expensive process. Preclinical animal models have become the gold standard for studying drug pharmacokinetic and toxicity parameters. However, the involvement of a huge number of animal subjects and inter-species pathophysiological variations between animals and humans has provoked a lot of debate, particularly because of ethical concerns. Although many efforts are being established by biotech and pharmaceutical companies for screening new chemical entities in vitro before preclinical trials, failures during clinical trials are still involved. Currently, a large number of two- dimensional (2D) in vitro assays have been developed and are being developed by researchers for the screening of compounds. Although these assays are helpful in screening a huge library of compounds and have shown perception, there is a significant lack in predicting human Absorption, Distribution, Metabolism, Excretion and Toxicology (ADME-Tox). As a result, these assays cannot completely replace animal models. The recent inventions in three-dimensional (3D) cell culture-based assays like organoids and micro-physiological systems have shown great potential alternative tools for predicting the compound pharmacokinetic and pharmacodynamic fate in humans. In this comprehensive review, we have summarized some of the most commonly used 2D in vitro assays and emphasized the achievements in next-generation 3D cell culture-based systems for predicting the compound ADME-Tox.